Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Amyloid Fibrils

Amyloid Fibrils

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A developmental shift in glucocorticoid receptor expression preserves glucocorticoid sensitivity in the adult suprachiasmatic nucleus.

PLoS biology·2026

Same author

Dopamine replacement therapy modulates DDC, prolactin and AOC3 levels in Parkinson's disease.

NPJ Parkinson's disease·2026

Same author

Dysregulation of sphingolipid-metabolizing enzymes in Friedreich's ataxia: <i>In vitro</i> and <i>in vivo</i> insights into therapeutic targeting.

iScience·2026

Same author

Reactive astrocytes mediate toxicity in iPSC derived dopaminergic neurons.

NPJ Parkinson's disease·2026

Same author

Temporal Interference Stimulation Enhances Neural Regeneration.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Synthetic nanoparticles for cell-type specific, spatially resolved loading and export of MiRNAs in neural cells.

Journal of nanobiotechnology·2026

Search research articles

Related Experiment Video

Updated: Feb 24, 2026

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

Alpha-synuclein oligomers: a new hope.

Nora Bengoa-Vergniory¹, Rosalind F Roberts², Richard Wade-Martins³

¹Department of Physiology, Anatomy and Genetics, Oxford Parkinson's Disease Centre, University of Oxford, South Parks Road, Oxford, OX1 3QT, UK.

Acta Neuropathologica

|August 14, 2017

Summary

Toxic oligomeric alpha-synuclein species drive Parkinson's disease pathology. New detection methods reveal their role in the brain, guiding therapeutic strategies targeting these harmful protein aggregates.

Keywords:

Aggregation Alpha-synuclein Detection-method Oligomers Parkinson’s

More Related Videos

Technique for Intranasal Administration of α-Synuclein Aggregates

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

Related Experiment Videos

Last Updated: Feb 24, 2026

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

Technique for Intranasal Administration of α-Synuclein Aggregates

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

Area of Science:

Neuroscience
Biochemistry
Pathology

Background:

Alpha-synuclein is implicated in Parkinson's disease (PD) pathogenesis.
The precise neurotoxic mechanisms of alpha-synuclein remain incompletely understood.
Toxic oligomeric species of alpha-synuclein are increasingly recognized as key drivers of PD pathology and propagation.

Purpose of the Study:

To review the evidence supporting the toxicity and prion-like behavior of alpha-synuclein oligomers.
To discuss how novel in situ detection methods advance the understanding of alpha-synuclein's role in the human brain.
To explore therapeutic strategies targeting alpha-synuclein oligomers in Parkinson's disease.

Main Methods:

Literature review of studies on alpha-synuclein oligomers and Parkinson's disease.
Assessment of evidence for toxicity and prion-like activity of alpha-synuclein oligomers.
Discussion of advancements in in situ detection techniques for alpha-synuclein species.

Main Results:

Oligomeric forms of alpha-synuclein exhibit significant toxicity and prion-like characteristics.
Sensitive detection methods enable specific identification of distinct oligomeric species in post-mortem brains.
These advancements are crucial for elucidating the role of alpha-synuclein in Parkinson's disease progression.

Conclusions:

Alpha-synuclein oligomers are critical pathological entities in Parkinson's disease.
Specific detection of these oligomers provides new insights into disease mechanisms.
Targeting alpha-synuclein oligomers represents a promising therapeutic avenue for Parkinson's disease.